Adding Hormone Therapy to PORT Might Not Benefit Patients with Recurrent Prostate Cancer and PSA of 0.5 ng/mL or Less By Ogkologos - March 5, 2026 133 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the POSEIDON meta-analysis of the MARCAP consortium Source RELATED ARTICLESMORE FROM AUTHOR ESMO Highlights the Importance of a Strong EU Commitment Towards Robust Science and Innovation Policies Following Meeting of EU Research Ministers on 29 May... Metastatic Breast Cancer: ESMO Clinical Practice Guideline EMA Recommends Extending Indications for Decitabine / Cedazuridine MOST POPULAR Science Surgery: ‘How are children’s cancers different from adult’s cancers?’ September 28, 2020 How to Cope With Waiting Periods During Cancer: An Expert Perspective June 1, 2023 New on NCI’s Websites for March 2022 March 16, 2022 Determining Fluid Requirements March 26, 2021 Load more HOT NEWS Stimulating the Immune System Shrinks Some Slow-Growing Lymphomas ESMO Immuno-Oncology Congress 2023, 6-8 December 2023, Geneva, Switzerland Meet Rosalie: St. Jude Children’s Research Hospital’s New Service Dog For... Colonoscopy after Positive FIT Test Cuts Risk of Colorectal Cancer Death
